INVELTYS市場：市場規模、予測、新たな洞察-2032年

INVELTYS（ロテプレドノールエタボネート/KPI-121）は、術後の眼炎症と眼痛を治療するナノ粒子眼用コルチコステロイド製剤です。INVELTYSは、他の眼科用副腎皮質ステロイドと同様に、上皮性単純ヘルペス角膜炎（樹枝状角膜炎）、ワクシニア、水痘を含む角膜および結膜のほとんどのウイルス性疾患、また眼のマイコバクテリア感染症および眼構造の真菌性疾患には禁忌です。

副腎皮質ステロイドは様々な誘因に対する炎症反応を抑制し、おそらく治癒を遅らせたり遅くしたりします。炎症に伴う浮腫、フィブリン沈着、毛細血管拡張、白血球遊走、毛細血管増殖、線維芽細胞増殖、コラーゲン沈着、瘢痕形成を抑制します。グルココルチコイドはグルココルチコイド受容体に結合し活性化しますが、グルココルチコイド/グルココルチコイド受容体に依存した炎症の調節に関与する分子メカニズムは確立されていません。しかし、コルチコステロイドはいくつかの独立した機序によってプロスタグランジンの産生を阻害します。

当レポートでは、主要7ヶ国におけるINVELTYS市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 術後疼痛におけるINVELTYSの概要

• 製品詳細
• 臨床開発
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 INVELTYS市場評価

• 術後疼痛におけるINVELTYSの市場展望
• 主要7ヶ国分析
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: INVELTYS, Clinical Trial Description, 2023
• Table 2: INVELTYS, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: INVELTYS Market Size in the 7MM, in USD million (2019-2032)
• Table 6: INVELTYS Market Size in the US, in USD million (2019-2032)
• Table 7: INVELTYS Market Size in Germany, in USD million (2019-2032)
• Table 8: INVELTYS Market Size in France, in USD million (2019-2032)
• Table 9: INVELTYS Market Size in Italy, in USD million (2019-2032)
• Table 10: INVELTYS Market Size in Spain, in USD million (2019-2032)
• Table 11: INVELTYS Market Size in the UK, in USD million (2019-2032)
• Table 12: INVELTYS Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: INVELTYS Market Size in the 7MM, USD million (2019-2032)
• Figure 2: INVELTYS Market Size in the United States, USD million (2019-2032)
• Figure 3: INVELTYS Market Size in Germany, USD million (2019-2032)
• Figure 4: INVELTYS Market Size in France, USD million (2019-2032)
• Figure 5: INVELTYS Market Size in Italy, USD million (2019-2032)
• Figure 6: INVELTYS Market Size in Spain, USD million (2019-2032)
• Figure 7: INVELTYS Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: INVELTYS Market Size in Japan, USD million (2019-2032)

"INVELTYS Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about INVELTYS for Postoperative pain in the seven major markets. A detailed picture of the INVELTYS for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the INVELTYS for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the INVELTYS market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

INVELTYS (loteprednol etabonate/KPI-121) is a nanoparticle ocular corticosteroid formulation to treat postoperative ocular inflammation and pain. INVELTYS, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

Dosage and administration

Instill one to two drops of INVELTYS into the affected eye twice daily, beginning the day after surgery and continuing throughout the first 2 weeks of the postoperative period.

Mechanism of action

Corticosteroids inhibit the inflammatory response to various inciting agents and probably delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not established. However, corticosteroids inhibit prostaglandin production through several independent mechanisms.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the INVELTYS description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on INVELTYS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the INVELTYS research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around INVELTYS.
• The report contains forecasted sales of INVELTYS for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for INVELTYS in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

INVELTYS Analytical Perspective by DelveInsight

• In-depth INVELTYS Market Assessment

This report provides a detailed market assessment of INVELTYS for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• INVELTYS Clinical Assessment

The report provides the clinical trials information of INVELTYS for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INVELTYS dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to INVELTYS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INVELTYS in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of INVELTYS from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the INVELTYS in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of INVELTYS?
• What is the clinical trial status of the study related to INVELTYS in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INVELTYS development?
• What are the key designations that have been granted to INVELTYS for Postoperative pain?
• What is the forecasted market scenario of INVELTYS for Postoperative pain?
• What are the forecasted sales of INVELTYS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to INVELTYS for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. INVELTYS Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. INVELTYS Market Assessment

• 5.1. Market Outlook of INVELTYS in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of INVELTYS in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of INVELTYS in the United States for Postoperative pain
  • 5.3.2. Market Size of INVELTYS in Germany for Postoperative pain
  • 5.3.3. Market Size of INVELTYS in France for Postoperative pain
  • 5.3.4. Market Size of INVELTYS in Italy for Postoperative pain
  • 5.3.5. Market Size of INVELTYS in Spain for Postoperative pain
  • 5.3.6. Market Size of INVELTYS in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of INVELTYS in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options